15d-PGJ2:: The anti-inflammatory prostaglandin?

被引：280
作者：
Scher, JU
Pillinger, MH
机构：
[1] NYU, Sch Med, Div Rheumatol, New York, NY 10003 USA
[2] Hosp Joint Dis & Med Ctr, New York, NY 10003 USA
[3] Manhattan VA Hosp, NY Harbor Healthcare Syst, New York, NY 10010 USA
来源：
CLINICAL IMMUNOLOGY | 2005年 / 114卷 / 02期
关键词：
prostaglandin; 15d-PGJ(2); PPAR-gamma; inflammation; PGD(2); H-PGDS; L-PGDS; NF-kappa B; Er; k;
D O I：
10.1016/j.clim.2004.09.008
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
15-Deoxy-Delta-(12,14)-prostaglandin J(2) (15d-PGJ(2)) is the most recently discovered prostaglandin. This cyclopentatione, the dehydration end product of PGD(2), differs from other prostaglandins in several respects. There is no specific prostaglandin synthase (PGS) leading to 15d-PGJ(2) production and no specific 15d-PGJ2 receptor has been identified to date. Instead, 15d-PGJ2 has been shown to act via PGD2 receptors (DP1 and DP2) and through interaction with intracellular targets. In particular, 15d-PGJ2 is recognized as the endogenous ligand for the intranuclear receptor PPARgamma. This property is responsible for many of the 15d-PGJ(2) anti-inflammatory functions. In this review, we summarize the current understanding of 15d-PGJ2 synthesis, biology and main effects both in molecular physiology and pathological states. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码：100 / 109
页数：10
相关论文
共 144 条
[1]   Activators of peroxisome proliferator-activated receptor γ have depot-specific effects on human preadipocyte differentiation [J].
Adams, M ;
Montague, CT ;
Prins, JB ;
Holder, JC ;
Smith, SA ;
Sanders, L ;
Digby, JE ;
Sewter, CP ;
Lazar, MA ;
Chatterjee, VKK ;
O'Rahilly, S .
JOURNAL OF CLINICAL INVESTIGATION, 1997, 100 (12) :3149-3153
[2]   PPAR gamma induces cell cycle withdrawal: inhibition of E2F/DP DNA-binding activity via down-regulation of PP2A [J].
Altiok, S ;
Xu, M ;
Spiegelman, BM .
GENES & DEVELOPMENT, 1997, 11 (15) :1987-1998
[3]  
Arimura A, 2001, J PHARMACOL EXP THER, V298, P411
[4]  
Attur M, 2003, ARTHRITIS RHEUM, V48, pS430
[5]   15-Deoxy-Δ12,14-prostaglandin J2 inhibits IL-10 and IL-12 production by macrophages [J].
Azuma, Y ;
Shinohara, R ;
Wang, PL ;
Ohura, K .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2001, 283 (02) :344-346
[6]   Biosynthesis of 15-deoxy-Δ12,14-PGJ2 and the litigation of PPARγ [J].
Bell-Parikh, LC ;
Ide, T ;
Lawson, JA ;
McNamara, P ;
Reilly, M ;
FitzGerald, GA .
JOURNAL OF CLINICAL INVESTIGATION, 2003, 112 (06) :945-955
[7]   Endothelial cell apoptosis induced by the peroxisome proliferator-activated receptor (PPAR) ligand 15-deoxy-Δ12,14-prostaglandin J2 [J].
Bishop-Bailey, D ;
Hla, T .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (24) :17042-17048
[8]   Evidence for the presence of peroxisome proliferator-activated receptor (PPAR) α and γ and retinoid Z receptor in cartilage -: PPARγ activation modulates the effects of interleukin-1β on rat chondrocytes [J].
Bordji, K ;
Grillasca, JP ;
Gouze, JN ;
Magdalou, J ;
Schohn, H ;
Keller, JM ;
Bianchi, A ;
Dauça, M ;
Netter, P ;
Terlain, B .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (16) :12243-12250
[9]   Differential expression of peroxisome proliferator-activated receptors (PPARs): Tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat [J].
Braissant, O ;
Foufelle, F ;
Scotto, C ;
Dauca, M ;
Wahli, W .
ENDOCRINOLOGY, 1996, 137 (01) :354-366
[10]   Use of the peroxisome proliferator-activated receptor (PPAR) γ ligand troglitazone as treatment for refractory breast cancer:: a phase II study [J].
Burstein, HJ ;
Demetri, GD ;
Mueller, E ;
Sarraf, P ;
Spiegelman, BM ;
Winer, EP .
BREAST CANCER RESEARCH AND TREATMENT, 2003, 79 (03) :391-397
12345678910